|
Memórias do Instituto Oswaldo Cruz
Fundação Oswaldo Cruz, Fiocruz
ISSN: 1678-8060 EISSN: 1678-8060
Vol. 90, Num. 4, 1995, pp. 525-528
|
Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol.
90(4): 525-528 Jul/Aug. 1995
A Randomized Trial of Amphotericin B alone or in
Combination with Itraconazole in the Treatment of
Mucocutaneous Leishmaniasis
LuisValda Rodriguez, Jean-Pierre Dedet*, Virginia Paredes,
Carmelo Mendoza, Fernando Cardenas
Servicio de Dermatologia, Hospital de Clinicas Universitario,
Miraflores, La Paz, Bolivia *Instituto Boliviano de Biologia
de Altura, La Paz, Bolivia
Code Number: OC95105
Size of Files:
Text: 15K
No associated graphics
A randomized trial of amphotericin B (AB) alone and in
combination with oral itraconazole (IZ) is carried out in two
groups of 10 mucocutaneous leishmaniasis patients from Bolivia
and Peru. AB+IZ combination is no better than AB monotherapy,
as far as efficacy and tolerability are concerned. No
antagonism was detected.
Key words : mucocutaneous leishmaniasis - treatment -
amphotericin B - itraconazole
Treating leishmaniasis is hampered by the toxicity and high
cost of the first line antileishmanial drugs. Mucosal
leishmaniasis due to Leishmania (Viannia) braziliensis
is often resistant to antimonials. There is a need to discover
new drugs or new therapeutic schedules.
Since the first use of amphotericin B (AB) in the treatment of
mucocutaneous leishmaniasis (MCL) by Sampaio et al.
(1960), this polyene antibiotic is the main drug for the
treatment of antimonial resistant mucocutaneous leishmaniasis
(MCL).
Itraconazole (IZ), an imidazole compound, exhibited, as well
as powerful antifungicidal activity, an effective
antileishmanial effect, mainly in cutaneous lesions, as
reported by Borelli (1987), Albanese et al. (1989) and
Dogra et al. (1990).
Confirming these observations, Valda Rodriguez and Calderon
(1988) showed a more rapid and efficient healing in some MCL
cases in which a prior IZ treatment was followed by AB. They
suggested a possible synergy between the two drugs, which
would permit, if confirmed, a reduced dose and duration of AB
treatment in MCL.
We report a randomized open trial of the combination IZ and
AB, versus AB alone, in MCL patients.
PATIENTS AND METHODS
The patients comprised 20 cases of MCL hospitalized between
January 1988 and December 1990 in the Dermatology Department
of the Hospital de Clinicas Universitario of the city of La
Paz (Bolivia).
All patients were male, with a mean age of 40 years (range 20
- 67 years). Sixteen came from Yungas and Alto-Beni (La Paz
department, Bolivia) and four from Puno province (Peru).
All patients had MCL lesions which were classified as:
moderate, with localization of the lesions to nasal, buccal
and pharyngeal mucosae (9 patients), or severe, with extension
to the larynx in addition to nose, mouth and pharynx (11
patients). The mean age of the lesions was 9 years (range 3 -
24 years).
The diagnosis of the disease was established at the Instituto
Boliviano de Biologia de Altura (IBBA) of La Paz (Bolivia).
Parasites were seen in May Grunwald-Giemsa stained smears in
three cases and culture was positive in six cases. In three
cases, the cultivated parasites were isoenzymatically
characterized and belonged to the L. braziliensis
taxon. Histology was performed on mucosal biopsies in all
cases, and processed at the Institut Pasteur (Paris, France).
The parasite was detected in tissue sections in nine cases.
All patients had positive Montenegro skin tests and indirect
fluorescent antibody technique (IFAT).
Before, during and after the treatment, the following
parameters were studied: ENT examination, full blood count,
liver function tests, blood glucose, urea, creatinine and
electrolytes; urine examination; electrocardiogram (ECG) and
chest X-ray. The laboratorial tests were repeated every ten AB
perfusions.
Four patients had positive serology for Trypanosoma
cruzi. All patients gave inform consent to participate
and were randomly assigned to two groups: (a) group A
comprised 10 patients (5 with moderate and 5 with severe
mucosal leishmaniasis), who received AB only. AB was given as
50 mg dissolved in 500 ml 5 % dextrose with 0.25 mg
dexamethasone. Infusions were administered over 8 hr, every
two days until lesions healed; (b) group B comprised 10
patients (4 with moderate and 6 with severe lesions), who
received the combination AB+IZ. IZ was given orally at a dose
of 200 mg/day for 41 days, 10 days preceding AB treatment and
then simultaneously with AB up to the 15th infusion (total
dose: 8,200 mg). AB was given as above until lesions
healed.
The follow-up of the patients included clinical evaluation,
ENT examination and IFAT antibody detection at months 1, 3, 6,
9 and 12 after the end of the treatment.
Statistical analysis of the data was by Student's test and
Mann-Whitney tests.
RESULTS
In group A B, healing of the lesions occurred at a mean dose
of 1,640 mg (range 1,250 - 2,500 mg). The mean duration of
the treatment to heal lesions was 70 days (range 51 - 109)
(Table).
Adverse effects were seen in six patients and consisted of
slight anaemia (3 cases), reversible renal impairment (2
cases) and ECG changes (ventricular extra systoles and
sub-endocardial ischaemia: 2 cases). These latter side-effects
occurred in two patients with associated chagasic cardiopathy.
All side-effects were transitory and disappeared after
completion of the treatment.
Relapse of the MCL occurred in a single patient, nine months
after the end of the treatment.
In group A B + I Z, healing of the lesions was achieved with a
mean dose of 1,400 mg of A B (range 750 - 2,500 mg). The mean
duration of the treatment to heal the lesion was 66 days
(range 36 - 117) (Table).
Adverse effects were seen in seven patients and consisted of
slight anaemia (3 cases), reversible renal impairment (2
cases), nausea and vomiting (2 cases) and sub-endocardial
ischaemia (1 case). All these disappeared after completion of
the treatment.
Relapse of the MCL occurred in two patients, two and six
months after the end of treatment.
TABLE. Summary of results of the efficacy and tolerability of
the amphotericin B alone (AB) and amphotericin Bin combination
with itraconazole (IZ)
-----------------------------------------------------------
Groups AB AB+IZ
------------------------------------------------------------
Dose producing healing 1.64g (1.25-2.5g) 1.4 (0.75-2.5g)
Time to healing 75 days(51-109 days) 66 days(36-117 days
Adverse effects 6/10 7/10
Relapse (months) 1(9) 2(2,6)
-------------------------------------------------------------
DISCUSSION
A B is considered by several authors, such as Martins Castro
(1972), as the most effective drug for treating MCL, including
antimonial resistant cases, because of a low relapse rate. An
optimal therapeutic effect is generally obtained with doses
less than 2 g (Llanos-Cuentas et al. 1988). In few
cases, the doses have nevertheless to be increased to 3 - 4 g,
above which irreversible renal damages may occur (Wolff &
Regnier 1984). Renal, cardiac and haematological toxicity
limites large scale A B utilization.
The combination of AB with other drugs, mainly antifungicidal
products, has been proposed, with the hope of obtaining
synergistic effects. This strategy could prevent the
development of resistance and could reduce toxic side effects
by a decrease in doses or duration of treatment.
The most commonly used combination is of AB and flucytosine
and has been used in the treatment of systemic infections due
to Candida and Cryptococcus (Bennet et al. 1979,
Dismukes et al. 1987, Sarosi 1990) and of chromomycosis
(Bopp 1976, Valda 1978).
The AB-fluocytosine combination is generally considered as an
additive synergy, which may be due to an increase of
flucytosine penetration resulting from increased permeability
of the fungal cell membranes produced by AB (Sande & Mandell
1988).
However, the combination of AB and imidazoles, mainly
ketoconazole, showed contradictory results. Medoff and
Kobayashi (1980) describe a theoretical antagonism between the
two drugs, resulting from common mechanisms of activity.
Experimental studies showed a synergy between AB and
ketoconazole against Cryptococcus neoformans (Graybill et
al. 1980, Odds 1982). The combination against Candida and
Aspergillus, was either synergistic (Odds 1982) or antagonic
(Jitsud & Feingold 1983).
Drug combinations including IZ are rarely described, probably
because of the superiority of this product to other imidazoles
and/or because of its recent commercialization. The
IZ-flucytosine combination was effective in patients infected
with cryptococcosis (Viviani et al. 1990) and with
chromoblastomycosis (Pradinaud & Bolzinger 1991).
An AB-IZ combination showed inconclusive results in the few
trials available. Among a group of 15 patients suffering with
invasive aspergillosis, Dupont (1990) observed that the
combination of IZ, AB and flucytosine resulted in
disappearance of the symptoms, and was well tolerated with
minor side effects, which did not limit treatment.
To our knowledge, the combination of AB and IZ in the
treatment of leishmaniasis has not been previously tested. The
present study showed that AB plus IZ was neither antagonic nor
synergistic. It resulted in healing at slightly lower doses
of AB and in slightly less time than in patients treated with
AB alone, but, in both cases, the results were not
significatively different. The relapse rate was better after
AB alone than after the combination.
Drug tolerance was similar in both groups of patients. In the
combined schedule, cumulative side-effects were not observed.
ECG changes can occur in patients infected simultaneously with
leishmaniasis and Chagas' disease, and require close
assessment of cardiac function when treated with AB.
In conclusion, the AB-IZ combination is no better than AB
monotherapy for MCL. The lack of antagonism suggests however
that the combination should be studied in other infections,
particularly in severe systemic fungal infections.
ACKNOWLEDGEMENTS
To Dr Cauwenberth (Division of Investigation, Janssen
Pharmaceutica, Belgium) for providing the itraconazole, Dr P
Ravisse (Institut Pasteur, Paris, France) for the pathological
revision of all biopsy material, Dr J Fernandez (CHU
Montpellier, France) for statistical analysis, and Dr RN
Davidson for kindly assisting with the english version. To the
following physicians or biologists for collaboration in the
development of the trial: Pr G Antezana, Pr R Bustillos, Dr C
David, Dr L Dimier-David, Dr P Lyevre, Dr F Rollano, Dr A
Quintela, Dr N de Nallar, Dr R Penaloza, Mrs H Miguez, Mrs C
Camacho and Dr M Munoz.
REFERENCES
Albanese G, Giorgetti P, Santagostino L, Crippa D, Sala G
1989. Cutaneous Leishmaniasis treatment with itraconozole.
Archs Derm 125: 1540-1542.
Bennet JE, Dismukes WE, Duma J, Medoff G, Sande MA, Gallis H,
Leonard J, Fields BT, Bradshaw M, Haywood H, Mc Gee ZA, Cate
TR, Cobbs CG, Warner JF, Alling DW 1979. A comparison of
Amphoterin B alone and combined with Flucytosine in the
treatment of Cryptoccal Meningitis. New Engl J Med 301:
126-131.
Bopp C 1976. Cura da Cromoblastomicose por novo metodo de
tratamento. Med Cutanea Ibero-Latino- america 4: 285-292.
Borelli D 1987. A clinical trial of Itraconazole in the
treatment of Deep Mycoses and Leishmaniasis. Rev Infect Dis
9: 557-563.
Dismukes WE, Cloud G, Gallis HA, Kerkering TM, Medoff G,
Graven PC, Kaplowitz LG, Fisher JF, Gregg CR, Bowles CA,
Shadomy S, Stamm LM, Diasio RB, Kaufman L, Soong SJ,
Blakwelder WC 1987. Treatment of Cryptococcal Meningitis with
combination of Amphotericin B and Flucytosine for four as
compared with six weeks. New Engl J Med 317: 334-341.
Dogra J, Aneja N, Lal BB, Mishra SN 1990. Cutaneous
leishmaniasis in India. Clinical experience with Itraconazole
(R51 211 Janssen). Int J Derm 29: 661-662.
Dupont B 1990. Itraconazole therapy in aspergillosis: Study
in 49 patients. J Am Acad Derm 23: 607-614.
Graybill JR, Williams DM, Vancutsem E, Drutz DJ 1980.
Combination therapy of Experimental Histoplasmosis and
Cryptococcis with Amphotericin B and Ketoconazole. Rev Infect
Dis 2: 551-558.
Jitsud I, Feingold DS 1983. Effect of Ketoconazole on the
fungicidal action of Amphotericin B in Candida albicans.
Antimicrob Ag and Chemotherapy 23: 185-187.
Llanos-Cuentas A, Cieza J, Cabezas J, Alvarez H, Echevarria J
1988. Eficacia de Anfotericina B en el tratamiento de
Leishmaniasis mucosa. V Jornadas Cient Univ Peruana Cayetano
Heredia.
Martins Castro R 1972. Tratamento da Leishmaniose Tegumentar
pela Anfotericina B. A proposito de 70 casos. Anais bras
Derm 47: 229-233.
Medoff G, Kobayashi GS 1980. Strategies in the treatment of
systemic fungal infections. New Engl J Med 302: 145-155.
Odds FC 1982. Interactions among Amphotericin B, 5
Flucytosine, Ketoconazole, and Miconazole against pathogenic
fungi in vitro. Antimicrob Ag and Chemotherapy 22:
763-770.
Pradinaud R, Bolzinger T 1991. Treatment of
chromoblastomycosis. J Am Acad Derm 25: 869-870.
Sampaio SAP, Godoy JT, Paiva L, Dillon N, Lacaz CS 1960. The
treatment of American (mucocutaneous) Leishmaniasis with
Amphotericin B. Archs Derm 82: 627-635.
Sande MA, Mandell GL 1988. Agentes Antimicrobianos. In Bases
Farmacologicas en Medicina, Goodman Gilman, Mexico: Edicion
Medica Panamericana, 1160 pp.
Sarosi GA 1990. Amphotericin B. Still the "gold standard"
for antifungal therapy. Postgrad Med 80: 151-166.
Valda Rodriguez L 1978. A proposito de la cromomicosis y de
su tratamiento. Archos Argent Derm 28: 159-168.
Valda Rodriguez L, Calderon Valle SW 1988. Itraconazole en el
tratamiento de la Leishmaniasis tegumentaria americana. Actual
Terap Derm 1: 376-381.
Viviani MA, Tortorano A M, Pagano A, Vigevani GM, Gubertini G,
Cristina S, Assaisso ML, Suter F, Farina C, Minetti B, Faggian
G, Caretta M, Di Fabrizio N, Vaglia A 1990. European
experience with Itraconazole in Systemic mycoses. J Am Acad
Derm 23: 587-593.
Wolff M, Regnier B 1984. Amphotericin B en 1984. Med Mal
Infect 14: 538-549.
Copyright 1995 Fundacao Oswaldo Cruz
|